A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care
A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care
-
Clinical Trial Information
Trial Contact: Tilme, Linda
Trial Phone: 321.843.5278
-
IRB No: 24.168.11
Protocol Abbrev: R668-EE-2328
Principal Investigator: Yamen Smadi, MD
Phase: Drug: Phase IV
Age Group: Pediatric
Treatment: N/A this is a registry
ClinicalTrials.gov ID: Pending
-
Objective
The primary objective is to collect data on the characteristics, treatment patterns, and outcomes among patients with EoE who initiate treatment with DUPIXENT in routine clinical practice in the U.S.
The secondary objective is to generate longer-term real-world safety data of DUPIXENT in EoE patients. -
Key Eligibility
A patient must meet all of the following criteria to be eligible for inclusion in this registry.
12 years of age or older at the baseline assessment
initiating treatment with DUPIXENT for EoE according to the USPI
Willing and able to comply with the required registry procedures and assessments
Able to understand and complete registry-related questionnaires (including adolescents)
Provide informed consent signed by registry participant or legally acceptable representative
